Adding Nalbuphine for Control of Intrathecal Morphine Pruritus
NCT ID: NCT04589429
Last Updated: 2021-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
70 participants
INTERVENTIONAL
2020-10-15
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Peripheral Itch Mechanisms Following Injection of Morphine
NCT04672382
Naloxone for the Treatment of Opioid-Induced Pruritus
NCT01071057
Reduction in Pain Intensity Following IV or Oral Pain-relieving Products
NCT02678416
Intravenous Acetaminophen and Morphine Versus Intravenous Morphine Alone for Acute Pain in the Emergency Department
NCT04148495
Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients
NCT03825887
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MN group
intrathecal morphine 300 micrograms+2mg nalbuphine
Morphine 10 MG/ML
intrathecal morphine 300 micrograms
Nalbuphine Hydrochloride 10 MG/ML
intrathecal nalbuphine 2mg.
M group
intrathecal morphine 300 micrograms
Morphine 10 MG/ML
intrathecal morphine 300 micrograms
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Morphine 10 MG/ML
intrathecal morphine 300 micrograms
Nalbuphine Hydrochloride 10 MG/ML
intrathecal nalbuphine 2mg.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-80yrs.
* Elective major abdominal surgery under general anesthesia.
Exclusion Criteria
* Skin or systemic disease with itching. Any condition which precludes performing spinal injection
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Minia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sohair Adeeb
Principle investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sohair A Megalla, MD
Role: PRINCIPAL_INVESTIGATOR
Anesthesia and ICU department, Faculty of Medicine, Minia University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
anesthesia&ICU department
Minya, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
678-9/2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.